<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01999530</url>
  </required_header>
  <id_info>
    <org_study_id>224/2012</org_study_id>
    <nct_id>NCT01999530</nct_id>
  </id_info>
  <brief_title>The Effects of Prazosin on Dopamine in Healthy Humans: A PET Pilot Study</brief_title>
  <official_title>Exploring the Effects of Prazosin on Basal Dopamine in Healthy Humans: A [11C]-(+)-PHNO PET Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre for Addiction and Mental Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ontario Lung Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre for Addiction and Mental Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether short term treatment with a antihypertensive
      medication prazosin, can influence the levels of a dopamine in the brain. We will examine the
      levels of dopamine in the the brain using Positron Emission Tomography (PET) and Magnetic
      Resonance Imaging (MRI). We hypothesize that there will be no significant changes in dopamine
      levels in healthy individuals taking prazosin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to find out whether short term treatment with a antihypertensive
      medication prazosin, can influence the levels of dopamine in the brain. We will examine the
      levels of dopamine in the the brain using Positron Emission Tomography (PET) and Magnetic
      Resonance Imaging (MRI). The study will involve three PET scans and one MRI. One PET scan
      will be performed before the participants take prazosin for approximately three weeks, and
      the last two PET scans will be performed after the prazosin medication phase. We hypothesize
      that there will be no significant changes in dopamine levels in healthy individuals taking
      prazosin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2013</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in [11C]-(+)-PHNO Binding (Measured as Binding Potential) in Dorsal Caudate (DC)</measure>
    <time_frame>3 weeks after taking prazosin</time_frame>
    <description>Binding potential (an estimate of the ratio of Bmax/kd) was measured by positron emission tomography to determine if taking prazosin alters the amount of tracer bound to receptors. A negative change in binding potential means a decrease in binding potential and a positive change in binding potential represents an increase. Bmax is the total density of receptors. kd is the affinity of a drug for the target</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Prazosin Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gradual upward titration to 15mg/day (or highest dose tolerated) for approximately three weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prazosin Hydrochloride</intervention_name>
    <description>Gradual upward titration to 15mg/day for approximately three weeks.</description>
    <arm_group_label>Prazosin Hydrochloride</arm_group_label>
    <other_name>Teva-Prazosin</other_name>
    <other_name>Prazosin</other_name>
    <other_name>Minipress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and females of any ethnic origin between 19 and 45 years old

        Exclusion Criteria:

          -  Use of any illicit drugs in past 3 months prior to randomization and/or have a current
             or past diagnosis of drug abuse/dependence (including alcohol)

          -  Current or past DSM-IV diagnosis of any Axis I psychiatric disorder

          -  Major psychiatric illness and/or substance dependence in first order relatives

          -  Current active or past suicidal ideation

          -  Baseline systolic blood pressure outside the normal range

          -  Current use of medications that could interact with prazosin (e.g. beta blockers,
             phosphodiesterasetype 5 inhibitors, indomethacin, verapamil, modafinil, clonidine)

          -  Current use or use during the previous month of medication that may affect the CNS at
             the time of scanning (e.g. neuroleptics, bupropion)

          -  Any significant abnormalities in baseline blood results (e.g. CBC, renal and hepatic
             indicators) or ECG readings that would preclude the use of prazosin

          -  Pregnancy, trying to become pregnant or breastfeeding

          -  Presence of metal objects in the body (e.g. some artificial joints, bone pins,
             surgical clips, skull plate, certain part of dental braces) or implanted electronic
             devices (e.g. cardiac pacemaker, neurostimulator), that preclude safe MR scanning

          -  Claustrophobia

          -  Participation in any nuclear medicine procedures that, including the dose received
             during participation in this study, will bring the total radiation dose over the
             currently approved guideline of 20mSv in a 12-month period

          -  Cardiovascular or cerebrovascular diseases

          -  History of or current neurological illnesses including seizure disorders, migraine,
             multiple sclerosis, movement disorders, head trauma, CVA or CNS tumor

          -  Abnormal body mass (defined as not within 20% of normal BMI

          -  Learning disability, amnesia or other conditions that impede memory and attention
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bernard Le Foll, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre for Addiction and Mental Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre for Addiction and Mental Health</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 1R8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.camh.net/research</url>
    <description>Information about research at the Centre for Addiction and Mental Health, Canada's largest mental health and addiction teaching</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>November 26, 2013</study_first_submitted>
  <study_first_submitted_qc>November 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2013</study_first_posted>
  <results_first_submitted>August 30, 2018</results_first_submitted>
  <results_first_submitted_qc>May 14, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 17, 2019</results_first_posted>
  <last_update_submitted>May 17, 2019</last_update_submitted>
  <last_update_submitted_qc>May 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centre for Addiction and Mental Health</investigator_affiliation>
    <investigator_full_name>Bernard Le Foll</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>prazosin</keyword>
  <keyword>dopamine</keyword>
  <keyword>healthy</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <keyword>PHNO</keyword>
  <keyword>scan</keyword>
  <keyword>effect</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prazosin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_type>Publication</doc_type>
      <doc_url>https://www.ncbi.nlm.nih.gov/pubmed/28233334</doc_url>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prazosin Hydrochloride</title>
          <description>Gradual upward titration to 15mg/day (or highest dose tolerated) for approximately three weeks.
Prazosin Hydrochloride: Gradual upward titration to 15mg/day for approximately three weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prazosin Hydrochloride</title>
          <description>Gradual upward titration to 15mg/day (or highest dose tolerated) for approximately three weeks.
Prazosin Hydrochloride: Gradual upward titration to 15mg/day for approximately three weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mixed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Changes in [11C]-(+)-PHNO Binding (Measured as Binding Potential) in Dorsal Caudate (DC)</title>
        <description>Binding potential (an estimate of the ratio of Bmax/kd) was measured by positron emission tomography to determine if taking prazosin alters the amount of tracer bound to receptors. A negative change in binding potential means a decrease in binding potential and a positive change in binding potential represents an increase. Bmax is the total density of receptors. kd is the affinity of a drug for the target</description>
        <time_frame>3 weeks after taking prazosin</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prazosin Hydrochloride</title>
            <description>Gradual upward titration to 15mg/day (or highest dose tolerated) for approximately three weeks.
Prazosin Hydrochloride: Gradual upward titration to 15mg/day for approximately three weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in [11C]-(+)-PHNO Binding (Measured as Binding Potential) in Dorsal Caudate (DC)</title>
          <description>Binding potential (an estimate of the ratio of Bmax/kd) was measured by positron emission tomography to determine if taking prazosin alters the amount of tracer bound to receptors. A negative change in binding potential means a decrease in binding potential and a positive change in binding potential represents an increase. Bmax is the total density of receptors. kd is the affinity of a drug for the target</description>
          <units>binding potential</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.1" lower_limit="1.4" upper_limit="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Prazosin Hydrochloride</title>
          <description>Gradual upward titration to 15mg/day (or highest dose tolerated) for approximately three weeks.
Prazosin Hydrochloride: Gradual upward titration to 15mg/day for approximately three weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Adverse events caused by prazosin</description>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bernard Le Foll</name_or_title>
      <organization>Centre for Addiction and Mental Health</organization>
      <phone>416-535-8501 ext 34772</phone>
      <email>bernard.lefoll@camh.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

